Amytrx Therapeutics has expanded their bioactive peptide platform beyond the original lead therapeutic molecule to include a multi-purpose drug delivery vehicle and imaging agent. In its recently completed Phase I/IIa clinical trial as part of an FDA-approved adaptive Phase I/II clinical protocol, AMTX-100 has shown potential in rapidly improving outcomes for patients with the inflammatory skin disorder, atopic dermatitis (AD). A Phase IIb in adult subjects with mild to moderate AD is planned to...